Abstract 4658: Novel paclitaxel medical nanoparticle formulation for breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4658
Abstract: Objectives: Paclitaxel (Ptxl) is currently the most common first-line therapeutic option for breast cancer (BrCa). However, adverse side effects and problems associated with chemo-resistance, limits its use in clinical settings. Nanoparticle mediated delivery can improve… read more here.
Keywords: formulation; breast cancer; nanoparticle formulation; cancer ... See more keywords